Majority of Patients with Colorectal, Lung Cancer Believe Surgery Is Cure
the Cancer Therapy Advisor take:
Participants in this study included 3,954 patients who underwent surgery for lung (30.3%) or colorectal (69.7%) cancer between 2003 and 2005. These patients were identified from a population- and health system-based survey from across the United States.
Approximately 80.0% of patients with lung cancer and 89.7% with colorectal cancer reported that they believed surgical resection would cure their cancer.
Of patients with stage IV lung cancer, 57.4% also believed surgery would cure their disease, along with 79.8% of patients with stage IV colorectal cancer.
The belief of curative surgery was found to be higher among patients with colorectal cancer versus those with lung cancer (OR = 2.27).
Results showed that single, female patients with an advanced tumor stage and having a high number of comorbidities were less likely to have the belief that surgery would cure their cancer. Patients who communicated effectively with their physician and shared a role in decision-making with their physician (OR = 1.16) or family (OR = 1.17) had a higher perception that surgery would be a cure.
However, patients who did not have hands-on participation in decision-making and reported a physician-controlled (OR = 0.56) or family-controlled (OR = 0.72) approach were less likely to believe surgery would be curative.
The study suggests improvement be made in the patient-physician engagement and communication mechanism. Additionally, the authors recommend that barriers regarding the discussion of goals of care with patients diagnosed with cancer be addressed.
A majority of patients with lung and colorectal cancer reported perceptions that surgery would cure their cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC
- Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC